dc.creator | KOUKOURAKIS I.M., ZYGOGIANNI A., KOULOULIAS V., KYRGIAS G., PANTELIADOU M., NANOS C., ABATZOGLOU I., KOUKOURAKIS M.I. | en |
dc.date.accessioned | 2023-01-31T08:45:15Z | |
dc.date.available | 2023-01-31T08:45:15Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.21873/anticanres.14797 | |
dc.identifier.issn | 02507005 | |
dc.identifier.uri | http://hdl.handle.net/11615/75279 | |
dc.description.abstract | Background/Aim: Hypofractionated accelerated radiotherapy (HypoAR) is widely applied for the treatment of early laryngeal cancer. Its role in locally advanced head-neck cancer (LA-HNC) is unexplored. Patients and Methods: We present results of a prospective trial on 124 patients with LAHNC, treated with radio-chemotherapy with three different HypoAR fractionations (3.5 Gy/day × 14-15 fractions, 2.7 Gy/day × 20-21 fractions, and 2.5 Gy/day × 21-22 fractions). Results: Protraction of the overall treatment time due to oropharyngeal mucositis was enforced in 18/57 laryngeal, 6/19 nasopharyngeal, and 15/48 cancer patients with other tumors. Regarding late toxicities, laryngeal edema grade 3 was noted in 5/57 patients with laryngeal cancer, while severe dysphagia was noted in 4/124 and tracheoesophageal fistula formation in 1/124 patients. The complete response rates obtained were 73%, 84%, and 67% in patients with laryngeal, nasopharyngeal, and other tumors, respectively. The 3-year locoregional progression-free survival was 58%, 73%, and 55%, respectively. Conclusion: HypoAR chemoradiotherapy is feasible, with acceptable early and late radiotherapy toxicities, response rates and LPFS. © 2021 International Institute of Anticancer Research. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Anticancer Research | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099701615&doi=10.21873%2fanticanres.14797&partnerID=40&md5=788a7d52cd7c7758045beddfd1958f04 | |
dc.subject | amifostine | en |
dc.subject | cetuximab | en |
dc.subject | chlorhexidine | en |
dc.subject | cisplatin | en |
dc.subject | codeine phosphate | en |
dc.subject | docetaxel | en |
dc.subject | fluorouracil | en |
dc.subject | mouthwash | en |
dc.subject | paracetamol | en |
dc.subject | posaconazole | en |
dc.subject | acute toxicity | en |
dc.subject | adenocarcinoma | en |
dc.subject | adult | en |
dc.subject | advanced cancer | en |
dc.subject | aged | en |
dc.subject | analgesia | en |
dc.subject | anaplastic carcinoma | en |
dc.subject | Article | en |
dc.subject | cancer combination chemotherapy | en |
dc.subject | cancer patient | en |
dc.subject | cancer radiotherapy | en |
dc.subject | cancer survival | en |
dc.subject | chemoradiotherapy | en |
dc.subject | clinical target volume | en |
dc.subject | computer assisted tomography | en |
dc.subject | conformal radiotherapy | en |
dc.subject | controlled clinical trial | en |
dc.subject | controlled study | en |
dc.subject | dysphagia | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | gross tumor volume | en |
dc.subject | head and neck cancer | en |
dc.subject | head and neck squamous cell carcinoma | en |
dc.subject | human | en |
dc.subject | hypofractionated accelerated radiotherapy | en |
dc.subject | hypofractionated radiotherapy | en |
dc.subject | hypopharynx cancer | en |
dc.subject | image guided radiotherapy | en |
dc.subject | induction chemotherapy | en |
dc.subject | intensity modulated radiation therapy | en |
dc.subject | larynx cancer | en |
dc.subject | larynx carcinoma | en |
dc.subject | larynx edema | en |
dc.subject | local disease free survival | en |
dc.subject | local progression free survival | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | mouth cancer | en |
dc.subject | mouth hygiene | en |
dc.subject | mucosa inflammation | en |
dc.subject | multiple cycle treatment | en |
dc.subject | mycosis | en |
dc.subject | nasopharynx cancer | en |
dc.subject | neck cancer | en |
dc.subject | organs at risk | en |
dc.subject | oropharynx | en |
dc.subject | oropharynx cancer | en |
dc.subject | pharyngitis | en |
dc.subject | physical examination | en |
dc.subject | planning target volume | en |
dc.subject | primary tumor | en |
dc.subject | priority journal | en |
dc.subject | progression free survival | en |
dc.subject | prospective study | en |
dc.subject | radiation dose fractionation | en |
dc.subject | radiation injury | en |
dc.subject | radiation response | en |
dc.subject | radiotherapy dosage | en |
dc.subject | sarcoma | en |
dc.subject | swallowing | en |
dc.subject | therapy delay | en |
dc.subject | tooth brushing | en |
dc.subject | tracheoesophageal fistula | en |
dc.subject | treatment duration | en |
dc.subject | volumetric modulated arc therapy | en |
dc.subject | adverse event | en |
dc.subject | cancer staging | en |
dc.subject | head and neck tumor | en |
dc.subject | intensity modulated radiation therapy | en |
dc.subject | Kaplan Meier method | en |
dc.subject | metastasis | en |
dc.subject | middle aged | en |
dc.subject | mortality | en |
dc.subject | multimodality cancer therapy | en |
dc.subject | pathology | en |
dc.subject | procedures | en |
dc.subject | prognosis | en |
dc.subject | treatment outcome | en |
dc.subject | very elderly | en |
dc.subject | young adult | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Chemoradiotherapy | en |
dc.subject | Combined Modality Therapy | en |
dc.subject | Dose Fractionation, Radiation | en |
dc.subject | Female | en |
dc.subject | Head and Neck Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Kaplan-Meier Estimate | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Metastasis | en |
dc.subject | Neoplasm Staging | en |
dc.subject | Prognosis | en |
dc.subject | Radiation Dose Hypofractionation | en |
dc.subject | Radiotherapy Dosage | en |
dc.subject | Radiotherapy, Intensity-Modulated | en |
dc.subject | Treatment Outcome | en |
dc.subject | Young Adult | en |
dc.subject | International Institute of Anticancer Research | en |
dc.title | Is locally advanced head-neck cancer one more candidate for accelerated hypofractionation? | en |
dc.type | journalArticle | en |